JP7420720B2 - ＦｃＲｎ抗体およびその使用方法 - Google Patents

ＦｃＲｎ抗体およびその使用方法 Download PDF

Info

Publication number
JP7420720B2
JP7420720B2 JP2020532551A JP2020532551A JP7420720B2 JP 7420720 B2 JP7420720 B2 JP 7420720B2 JP 2020532551 A JP2020532551 A JP 2020532551A JP 2020532551 A JP2020532551 A JP 2020532551A JP 7420720 B2 JP7420720 B2 JP 7420720B2
Authority
JP
Japan
Prior art keywords
sequence
antibody
cdr
seq
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020532551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506786A5 (cg-RX-API-DMAC10.html
JP2021506786A (ja
Inventor
レオナ イー． リング
ダレル ニックス
ニコラス エー． チルフォン
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021506786A publication Critical patent/JP2021506786A/ja
Publication of JP2021506786A5 publication Critical patent/JP2021506786A5/ja
Priority to JP2023177190A priority Critical patent/JP7690538B2/ja
Application granted granted Critical
Publication of JP7420720B2 publication Critical patent/JP7420720B2/ja
Priority to JP2025089576A priority patent/JP7904366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2020532551A 2017-12-13 2018-12-13 ＦｃＲｎ抗体およびその使用方法 Active JP7420720B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023177190A JP7690538B2 (ja) 2017-12-13 2023-10-13 ＦｃＲｎ抗体およびその使用方法
JP2025089576A JP7904366B2 (ja) 2017-12-13 2025-05-29 ＦｃＲｎ抗体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598402P 2017-12-13 2017-12-13
US62/598,402 2017-12-13
US201862701354P 2018-07-20 2018-07-20
US62/701,354 2018-07-20
PCT/US2018/065568 WO2019118791A1 (en) 2017-12-13 2018-12-13 Fcrn antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177190A Division JP7690538B2 (ja) 2017-12-13 2023-10-13 ＦｃＲｎ抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2021506786A JP2021506786A (ja) 2021-02-22
JP2021506786A5 JP2021506786A5 (cg-RX-API-DMAC10.html) 2021-05-13
JP7420720B2 true JP7420720B2 (ja) 2024-01-23

Family

ID=65041911

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020532551A Active JP7420720B2 (ja) 2017-12-13 2018-12-13 ＦｃＲｎ抗体およびその使用方法
JP2023177190A Active JP7690538B2 (ja) 2017-12-13 2023-10-13 ＦｃＲｎ抗体およびその使用方法
JP2025089576A Active JP7904366B2 (ja) 2017-12-13 2025-05-29 ＦｃＲｎ抗体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023177190A Active JP7690538B2 (ja) 2017-12-13 2023-10-13 ＦｃＲｎ抗体およびその使用方法
JP2025089576A Active JP7904366B2 (ja) 2017-12-13 2025-05-29 ＦｃＲｎ抗体およびその使用方法

Country Status (11)

Country Link
US (2) US11773168B2 (cg-RX-API-DMAC10.html)
EP (1) EP3723802A1 (cg-RX-API-DMAC10.html)
JP (3) JP7420720B2 (cg-RX-API-DMAC10.html)
KR (2) KR20260008175A (cg-RX-API-DMAC10.html)
CN (1) CN111712259A (cg-RX-API-DMAC10.html)
AU (1) AU2018386193B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020011310A2 (cg-RX-API-DMAC10.html)
CA (1) CA3085751A1 (cg-RX-API-DMAC10.html)
IL (1) IL275070A (cg-RX-API-DMAC10.html)
SG (1) SG11202005021PA (cg-RX-API-DMAC10.html)
WO (1) WO2019118791A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024016042A (ja) * 2017-12-13 2024-02-06 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
CA3183153A1 (en) * 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
CN116782939A (zh) * 2020-11-06 2023-09-19 动量制药公司 FcRn抗体及其使用方法
CA3200972A1 (en) * 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
MX2023012032A (es) * 2021-04-12 2023-12-08 Momenta Pharmaceuticals Inc Composiciones y métodos para tratar la miastenia gravis pediátrica.
CN116234827B (zh) * 2021-09-03 2026-07-14 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
CN114129730A (zh) * 2021-09-16 2022-03-04 宁夏大学 FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用
MX2024007806A (es) * 2022-01-17 2024-07-04 argenx BV Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos.
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
JP2026526949A (ja) 2023-07-31 2026-08-10 メディトックス インク． 抗体及びそれを含む免疫疾患治療用薬学的組成物
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025186787A1 (en) * 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523351A (ja) 2008-04-25 2011-08-11 ダイアックス、コープ ＦｃＲｎに対する抗体及びその使用
JP7094941B2 (ja) 2016-07-29 2022-07-04 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CA2534973A1 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatment of auto/allo immune conditions
CN101124245A (zh) 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN102549016B (zh) 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
US9067997B2 (en) * 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
BR112013030352B1 (pt) 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2991666B1 (en) 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
CA3022547A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
JP6913527B2 (ja) 2017-06-22 2021-08-04 株式会社小松製作所 油圧ポンプおよびモータ
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EP3762027A4 (en) 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
IL280280B2 (en) 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
JP7518821B2 (ja) 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
CA3148826A1 (en) 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
CA3200972A1 (en) 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523351A (ja) 2008-04-25 2011-08-11 ダイアックス、コープ ＦｃＲｎに対する抗体及びその使用
JP7094941B2 (ja) 2016-07-29 2022-07-04 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Seminars in Fetal & Neonatal Medicine，2016年，21，19-27

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024016042A (ja) * 2017-12-13 2024-02-06 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP7690538B2 (ja) 2017-12-13 2025-06-10 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP2025143252A (ja) * 2017-12-13 2025-10-01 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP7904366B2 (ja) 2017-12-13 2026-08-12 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法

Also Published As

Publication number Publication date
US11773168B2 (en) 2023-10-03
AU2018386193A1 (en) 2020-06-25
BR112020011310A2 (pt) 2020-11-17
SG11202005021PA (en) 2020-07-29
JP7904366B2 (ja) 2026-08-12
KR102904658B1 (ko) 2025-12-29
AU2018386193A8 (en) 2020-07-02
US20240158509A1 (en) 2024-05-16
KR20260008175A (ko) 2026-01-15
US20220064290A1 (en) 2022-03-03
JP2021506786A (ja) 2021-02-22
EP3723802A1 (en) 2020-10-21
CN111712259A (zh) 2020-09-25
WO2019118791A1 (en) 2019-06-20
CA3085751A1 (en) 2019-06-20
AU2018386193B2 (en) 2025-04-24
NZ765250A (en) 2026-02-27
JP2024016042A (ja) 2024-02-06
JP7690538B2 (ja) 2025-06-10
JP2025143252A (ja) 2025-10-01
KR20200098604A (ko) 2020-08-20
IL275070A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
JP7690538B2 (ja) ＦｃＲｎ抗体およびその使用方法
JP7442575B2 (ja) Ｆｃｒｎ抗体及びその使用方法
US20220259308A1 (en) Fcrn antibodies and methods of use thereof
HK40104376A (en) Fcrn antibodies and methods of use thereof
BR122025025099A2 (pt) Anticorpos contra fcrn, usos dos mesmos e composições
EA050428B1 (ru) АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40002836A (en) Fcrn antibodies and methods of use thereof
HK40002836B (en) Fcrn antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200805

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210330

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210729

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240111

R150 Certificate of patent or registration of utility model

Ref document number: 7420720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150